Literature DB >> 23832665

Distinct FAK activities determine progenitor and mammary stem cell characteristics.

Ming Luo1, Xiaofeng Zhao, Song Chen, Suling Liu, Max S Wicha, Jun-Lin Guan.   

Abstract

Mammary stem cells (MaSC) and progenitor cells are important for mammary gland development and maintenance and may give rise to mammary cancer stem cells (MaCSC). Yet, there remains limited understanding of how these cells contribute to tumorigenesis. Here, we show that conditional deletion of focal adhesion kinase (FAK) in embryonic mammary epithelial cells (MaEC) decreases luminal progenitors and basal MaSCs, reducing their colony-forming and regenerative potentials in a cell-autonomous manner. Loss of FAK kinase activity in MaECs specifically impaired luminal progenitor proliferation and alveologenesis, whereas a kinase-independent activity of FAK supported ductal invasion and basal MaSC activity. Deficiency in luminal progenitors suppressed tumorigenesis and MaCSC formation in a mouse model of breast cancer. In contrast with the general inhibitory effect of FAK attenuation, inhibitors of FAK kinase preferentially inhibited proliferation and tumorsphere formation of luminal progenitor-like, but not MaSC-like, human breast cancer cells. Our findings establish distinct kinase-dependent and -independent activities of FAK that differentially regulate luminal progenitors and basal MaSCs. We suggest that targeting these distinct functions may tailor therapeutic strategies to address breast cancer heterogeneity more effectively.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23832665      PMCID: PMC3766468          DOI: 10.1158/0008-5472.CAN-13-1351

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A.

Authors:  Daisuke Yamaji; Risu Na; Yonatan Feuermann; Susanne Pechhold; Weiping Chen; Gertraud W Robinson; Lothar Hennighausen
Journal:  Genes Dev       Date:  2009-10-15       Impact factor: 11.361

2.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.

Authors:  Chad J Creighton; Xiaoxian Li; Melissa Landis; J Michael Dixon; Veronique M Neumeister; Ashley Sjolund; David L Rimm; Helen Wong; Angel Rodriguez; Jason I Herschkowitz; Cheng Fan; Xiaomei Zhang; Xiaping He; Anne Pavlick; M Carolina Gutierrez; Lorna Renshaw; Alexey A Larionov; Dana Faratian; Susan G Hilsenbeck; Charles M Perou; Michael T Lewis; Jeffrey M Rosen; Jenny C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-03       Impact factor: 11.205

3.  Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells.

Authors:  Ming Luo; Huaping Fan; Tamas Nagy; Huijun Wei; Chenran Wang; Suling Liu; Max S Wicha; Jun-Lin Guan
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

4.  Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.

Authors:  Yuliya Pylayeva; Kelly M Gillen; William Gerald; Hilary E Beggs; Louis F Reichardt; Filippo G Giancotti
Journal:  J Clin Invest       Date:  2009-01-19       Impact factor: 14.808

5.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.

Authors:  Elgene Lim; François Vaillant; Di Wu; Natasha C Forrest; Bhupinder Pal; Adam H Hart; Marie-Liesse Asselin-Labat; David E Gyorki; Teresa Ward; Audrey Partanen; Frank Feleppa; Lily I Huschtscha; Heather J Thorne; Stephen B Fox; Max Yan; Juliet D French; Melissa A Brown; Gordon K Smyth; Jane E Visvader; Geoffrey J Lindeman
Journal:  Nat Med       Date:  2009-08-02       Impact factor: 53.440

6.  Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer.

Authors:  Paolo P Provenzano; David R Inman; Kevin W Eliceiri; Hilary E Beggs; Patricia J Keely
Journal:  Am J Pathol       Date:  2008-10-09       Impact factor: 4.307

7.  GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model.

Authors:  Hosein Kouros-Mehr; Seth K Bechis; Euan M Slorach; Laurie E Littlepage; Mikala Egeblad; Andrew J Ewald; Sung-Yun Pai; I-Cheng Ho; Zena Werb
Journal:  Cancer Cell       Date:  2008-02       Impact factor: 31.743

Review 8.  Signal transduction by focal adhesion kinase in cancer.

Authors:  Jihe Zhao; Jun-Lin Guan
Journal:  Cancer Metastasis Rev       Date:  2009-06       Impact factor: 9.264

9.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.

Authors:  Emmanuelle Charafe-Jauffret; Christophe Ginestier; Flora Iovino; Julien Wicinski; Nathalie Cervera; Pascal Finetti; Min-Hee Hur; Mark E Diebel; Florence Monville; Julie Dutcher; Marty Brown; Patrice Viens; Luc Xerri; François Bertucci; Giorgio Stassi; Gabriela Dontu; Daniel Birnbaum; Max S Wicha
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

10.  Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo.

Authors:  Hicham Lahlou; Virginie Sanguin-Gendreau; Margaret C Frame; William J Muller
Journal:  Breast Cancer Res       Date:  2012-02-28       Impact factor: 6.466

View more
  34 in total

Review 1.  Identifying and targeting tumor-initiating cells in the treatment of breast cancer.

Authors:  Wei Wei; Michael T Lewis
Journal:  Endocr Relat Cancer       Date:  2015-04-15       Impact factor: 5.678

2.  Targeted therapy against cancer stem cells.

Authors:  Tao Yang; Kiera Rycaj
Journal:  Oncol Lett       Date:  2015-05-04       Impact factor: 2.967

3.  Disrupting the scaffold, an alternative approach to inhibiting FAK.

Authors:  Song Chen; Michael Haas; Shaogang Sun
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

4.  Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15.

Authors:  Vita Golubovskaya; Shalana O'Brien; Baotran Ho; Melissa Heffler; Jeffrey Conroy; Quang Hu; Dan Wang; Song Liu; William G Cance
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-06       Impact factor: 4.553

Review 5.  Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance.

Authors:  Jonathan Cooper; Filippo G Giancotti
Journal:  Cancer Cell       Date:  2019-03-18       Impact factor: 31.743

6.  Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.

Authors:  Irina M Shapiro; Vihren N Kolev; Christian M Vidal; Yuwaraj Kadariya; Jennifer E Ring; Quentin Wright; David T Weaver; Craig Menges; Mahesh Padval; Andrea I McClatchey; Qunli Xu; Joseph R Testa; Jonathan A Pachter
Journal:  Sci Transl Med       Date:  2014-05-21       Impact factor: 17.956

Review 7.  New Opportunities and Challenges to Defeat Cancer Stem Cells.

Authors:  Erika K Ramos; Andrew D Hoffmann; Stanton L Gerson; Huiping Liu
Journal:  Trends Cancer       Date:  2017-09-21

8.  The STAT5-regulated miR-193b locus restrains mammary stem and progenitor cell activity and alveolar differentiation.

Authors:  Kyung Hyun Yoo; Keunsoo Kang; Yonatan Feuermann; Seung Jin Jang; Gertraud W Robinson; Lothar Hennighausen
Journal:  Dev Biol       Date:  2014-09-16       Impact factor: 3.582

Review 9.  FAK in cancer: mechanistic findings and clinical applications.

Authors:  Florian J Sulzmaier; Christine Jean; David D Schlaepfer
Journal:  Nat Rev Cancer       Date:  2014-08-07       Impact factor: 60.716

10.  FAK Promotes Early Osteoprogenitor Cell Proliferation by Enhancing mTORC1 Signaling.

Authors:  Shuqun Qi; Xiumei Sun; Han Kyoung Choi; Jinfeng Yao; Li Wang; Guomin Wu; Yun He; Jian Pan; Jun-Lin Guan; Fei Liu
Journal:  J Bone Miner Res       Date:  2020-06-05       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.